Colorectal signet-ring cell carcinoma treated with FOLFOX plus panitumumab

Pediatr Int. 2022 Jan;64(1):e15374. doi: 10.1111/ped.15374.

Authors

Satoru Matsushima¹, Ryoji Kobayashi¹, Hirozumi Sano¹, Daiki Hori¹, Masato Yanagi¹, Junichi Goto², Kunihiko Kobayashi¹

Affiliations

¹ Department of Hematology/Oncology for Children and Adolescents, Sapporo Hokuyu Hospital, Sapporo, Japan.
² Department of Surgery, Sapporo Hokuyu Hospital, Sapporo, Japan.

PMID: 36169041
DOI: 10.1111/ped.15374

No abstract available

Keywords: FOLFOX; children; colorectal carcinoma; panitumumab; signet-ring cell carcinoma.

MeSH terms

Carcinoma, Signet Ring Cell* / diagnosis
Carcinoma, Signet Ring Cell* / drug therapy
Carcinoma, Signet Ring Cell* / pathology
Colorectal Neoplasms* / drug therapy
Colorectal Neoplasms* / pathology
Humans
Panitumumab / therapeutic use

Substances

Panitumumab